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Cancer metabolism differs remarkably from the metabolism of healthy surrounding tissues, and it is
extremely heterogeneous across cancer types. While these metabolic differences provide promising
avenues for cancer treatments, much work remains to be done in understanding how metabolism is
rewired in malignant tissues. To that end, constraint-based models provide a powerful computational
tool for the study of metabolism at the genome scale. To generate meaningful predictions, however,
these generalized human models must first be tailored for specific cell or tissue sub-types. Here
we first present two improved algorithms for (1) the generation of these context-specific metabolic
models based on omics data, and (2) Monte-Carlo sampling of the metabolic model flux space. By
applying these methods to generate and analyze context-specific metabolic models of diverse solid
cancer cell line data, and primary leukemia pediatric patient biopsies, we demonstrate how the
methodology presented in this study can generate insights into the rewiring differences across solid
tumors and blood cancers.
Keywords: Genome-scale metabolic reconstructions, constraint-based models, tissue-specific models,
Flux Balance Analysis, cancer metabolism.
Introduction
Cancer tissues exhibits significant metabolic differences when compared to their healthy coun-
terparts, such as the Warburg effect1 and glutamine addiction.2 In recent years it has been
revealed that these metabolic transformations are largely driven by oncogenes and subdued by
tumor suppressor genes.3,4 This regulation suggests that cancer metabolism plays an important
role in tumor progression, as opposed to being a consequence of the tumor microenvironment.5
These findings have led to a renewed interest in the field of cancer metabolism,6 with particular
interest in exploiting metabolic differences as therapeutic targets.7 Cancer metabolism, how-
ever, is also extremely heterogeneous across cancer types,8 and treatments targeting metabolic
pathways need to be carefully tailored to specific cancer phenotypes. Consequently, a better
understanding of the metabolic differences across cancer sub-types, and between healthy and
cancerous tissues will greatly assist the development of novel therapeutic strategies.7,8
Genome-Scale Models: To help elucidate the metabolic differences between cancer and
healthy tissues, computational approaches can be extremely helpful. In particular, genome-
scale models (GEMs) have proven extremely useful in studying human metabolism at the
genome level,9,10 with many studies dedicated specifically to cancer metabolism.11–13 These




























































studies have, for example, identified glycosaminoglycans as a marker for clear cell renal cell
carcinoma,14 identified carnitine palmitoyltransferase 1 as a potential target for hepatocellular
carcinoma,15 and identified MLYCD as a potential target for leukemia and kidney cancer.16
GEMs are defined at the core by a stoichiometric matrix S, where each row corresponds
to a metabolite, each column to a metabolic reaction, and each entry to the stoichiometric
coefficient of that particular metabolite in that particular reaction.17 For any given stoichio-
metric matrix , flux distribution column vectors (v) can be defined where each element vi gives
the metabolic flux (e.g. rate of metabolite conversion) through each reaction i. The matrix
multiplication S ·v = m then yields a vector m where each element mj gives the rate of change
of concentration of metabolite j given the reaction fluxes defined by v. A steady-state flux
distribution is one where S · v = 0. A more detailed description of the constraint-based model
formulation is available in the supplemental information.
Metabolic Model Analysis: Although a wide array of methods have been developed
to study GEMs,18 many of them are dependent on an objective function, which is most often
assumed to be cellular growth.19 Mammalian cells, however, do not have a well established
objective, and do not seek to optimize biomass production. One prominent unbiased and
objective-independent method for GEM analysis, suited for the study of mammalian cells,
is Monte-Carlo sampling (MCS). This method finds normally distributed steady-state flux
distributions inside the solution space of S ·v = 0 defined by lower (lb) and upper (ub) reaction
bounds, such that lbi ≤ vi ≤ ubi. Valuable insight into the metabolic capabilities of the model
in question can be obtained by analyzing how different MCS conditions (e.g. different lower
and upper bounds) affect the sampled reaction flux values. This approach has been used, for
example, to model the metabolic exchange between M. tuberculosis and human macrophages,20
and between different cell types in the human brain;21 to study aspirin resistance in platelet
cells;22 and to characterize metabolic differences between healthy and cancerous tissues.23
Mammals also have a complex and compartmentalized metabolism, where not every
metabolic reaction takes place in all cells of the body. In order to generate predictions specific
to different cell types, cancer categories or patients, generalized human GEMs then need to be
tailored to specific contexts.24 We recently introduced the Cost Optimization Reaction Depen-
dency Assessment (CORDA) tissue-specific algorithm,23 which builds tissue-specific metabolic
models based on omics data and a generalized human metabolic reconstruction. The algorithm
is based on a dependency assessment (DA), where reactions associated with little experimen-
tal evidence, called negative confidence reactions (NC), are assigned an arbitrarily high cost.
This cost is then minimized while enforcing a small flux through medium (MC) or high (HC)
confidence reactions (i.e. reactions with medium or considerable experimental evidence) in
order to identify which NC reactions are beneficial for MC or HC reactions to carry flux. This
DA is then used to build a tissue-specific model including all HC reactions and as many MC
reactions as possible, while minimizing the inclusion of NC reactions. For additional details
on the original algorithm we refer readers to the original CORDA publication.23
Need for New Analyses: MCS of large metabolic networks is computationally expensive,
and static approaches are only feasible for extremely small networks.25 For MCS of higher
dimensional networks, the Artificially Centered Hit and Run (ACHR) algorithm26 is most




























































frequently used. Given a set of points, or steady-state flux distributions, inside the solution
space, ACHR calculates a center point as the average of all points, then moves each point
i randomly along the directional vector defined by the trajectory between the center and
another random point j. ACHR sampling of large networks can be extremely time consuming,
however, and even small relative increments in computational efficiency can lead to fewer
hours of computational time. Although alternatives to ACHR have been proposed, many of
these methods are limited by sample distributions that are significantly different than ACHR
outputs,27–29 by their dependence on objective functions,27 by long computational times,30 or
by lack of validation and parametrization in larger metabolic networks.31
Introduction of CORDA2 and mfACHR: Here we present two improved algorithms
for the study of human GEMs. We first introduce an improved version of the CORDA al-
gorithm to build tissue-specific metabolic models,23 referred to here as CORDA2 . CORDA2
yields tissue models very similar to the ones given by the previous algorithm, but it is con-
siderably faster than CORDA computationally. CORDA2 is also noise-independent, thus pro-
viding unique model outputs for any given set of parameters, which facilitates the comparison
of metabolic models across different modeling conditions (i.e. different cancer categories). We
next introduce a new formulation of the ACHR algorithm,26 referred to here as the matrix-form
ACHR (mfACHR), which performs significantly faster than previous formulations.
Integrating the two new methods, we generate a panel of cell-line specific metabolic models
using CORDA2 and experimental data from the Human Protein Atlas32 (HPA), and illustrate
how flux samples generated using mfACHR can provide valuable insights into the metabolic
profile of different cancer types, including pediatric leukemia. While we had previously shown
that MCS of CORDA models can identify metabolic differences between healthy and cancerous
tissues, here we show that this framework can also pinpoint metabolic differences between
different cancer categories. The methods presented in this study provide significant advances
in the generation and analysis of context-specific metabolic models.
Methods
Cost Optimization Reaction Dependency Assessment 2
In this work we present two modifications to CORDA, defining a new version of the algorithm
referred to here as CORDA2 . First, in the original algorithm, reversible reactions were split
into forward and backward rates during every DA to ensure cost production regardless of di-
rectionality. That is, a reaction ‘A⇔ B’ was split into ‘A⇒ B+cost’ and ‘B ⇒ A+cost’. Since
thousands of DAs are performed throughout the model building process, this modification
was then repeated thousands of times during the algorithm. In CORDA2 , this modification
is performed at the beginning of the algorithm, and forward and backward rates are treated
separately throughout the model building process, speeding the computational time. Further-
more, while in CORDA the reaction directionality in the tissue-model was imported from
the generalized human reconstruction, CORDA2 assigns directionality based on whether the
forward, backward, or both reaction parts are included in the final tissue model.
Second, pathways with similar costs are captured in CORDA by adding a small amount
of noise to reaction costs during every DA. This noise-driven approach leads to different




























































Fig. 1. Representation of the CORDA2 and mfACHR algorithms. (A) Identification of undesirable
reactions (red) beneficial for the desirable reaction (blue) to carry flux through three DAs. Pathways taken
during each DA are highlighted, and H represents the set of undesirable reactions taken up to that point.
After an undesirable reaction is used, its cost (e) is increased. The process is repeated until H is unchanged.
(B) gpSampler moves one point at a time, 50 steps at a time. The mfACHR algorithm identifies all possible
directions of movement at once and moves all points simultaneously. Vectors defining the trajectory of move-
ment, taken as the difference between j and the center point, and the corresponding path of movement of i
are color-coded. (C) During parallelization of the MCS process, the matrix of sampled points is divided into
2 cores, which are sampled for 50 steps, then re-combined.
reconstructions after every run of the algorithm, and it is not guaranteed to include every
alternative pathway. This approach is also inefficient since the same pathway can be sampled
multiple times. In CORDA2 , only undesirable reactions are assigned an arbitrarily high cost
(while in CORDA all reactions received a basal cost value). This cost is then minimized during
the DA, and the high cost reactions used are saved in a set H . The cost associated with the
reactions in H is then increased, and the DA is performed again (Fig. 1A). This process
is repeated iteratively until H is unchanged. This way, once a pathway is used, its cost is
increased and another pathway with similar but now slightly lower cost is identified in the
next DA. Additional details of the CORDA2 formulation, as well as the MATLAB code for
its implementation, can be found in the supplemental information.
Matrix-Form Artificially Centered Hit and Run
One of the most widely implemented ACHR formalisms is gpSampler .33 GpSampler starts by
moving a given point 50 steps as described by the ACHR algorithm, then repeats the process
for each point being sampled. This whole process is then repeated n50 times for a total of
n ACHR steps (Fig. 1B). Here we propose a slightly different ACHR formulation, termed
matrix-form ACHR (mfACHR). In mfACHR, all possible directions of movement are first




























































calculated as the directional vectors defined by each sampled point and the center (dashed
lines in Fig. 1B). These trajectories are then randomly assigned to each point, and each
point is moved randomly along its assigned direction of movement (solid lines in Fig. 1B)
within the bounds of the solution space. This whole process is repeated a total of n times for a
desired number of steps. Both gpSampler and mfACHR can also be implemented in multiple
cores. For that, the points being sampled are first divided into i groups, i being the number of
cores used. Each group is then assigned to a core and mixed for 50 steps. All points are then
re-combined and the process is repeated n50 times for a total of n steps (Fig. 1C).
Cancer Cell Proteomics and Model Generation
Cell line gene and protein expression data were obtained from the HPA32 in order to build
the cell-line specific models. Gene expression data was measured using RNA-seq and protein
expression was measured by immunohistochemistry using an extensive library of well validated
antibodies. Forty-four models were generated using gene expression data and fifty-two models
were generated using the proteomics data. Protein expression was available for 523 (35.0%)
gene products, and gene expression data was available for 1,474 (98.7%) of the 1,494 unique
genes in the generalized human reconstruction Recon1.34 All gene and protein expression values
were categorized into not detected, low/medium, and high expression in line with threshold
values from the HPA, then used to categorize reaction confidence values used in the CORDA2
algorithm. Following the reconstruction all models were sampled using mfACHR. Details of
how these models were generated and sampled can be found in the supplemental information.
For additional details on how the dataset was collected we refer readers to the HPA.32
Leukemia Patient Samples: Pediatric leukemia data was obtained from bone marrow
biopsies of 95 acute myeloid leukemia (AML), 57 B-cell acute lymphoblastic leukemia (B-ALL),
and 16 T-cell acute lymphoblastic leukemia (T-ALL) pediatric patients, and were collected
at the Texas Children’s Hospital. Protein expression level was measured using reverse phase
protein array (RPPA) using 194 strictly validated antibodies.35 Additional information on the
pediatric leukemia data is available in the supplemental information.
Results and Discussion
Results of our study demonstrate the robustness of the CORDA2 and mfACHR methods, and
their utility in analyzing diverse cell line and primary leukemia cancer metabolism. A summary
of the CORDA2 and mfACHR validation is provided below, while a complete description of
the algorithm validation and analysis is provided in the supplemental information.
CORDA2 Validation
In order to validate the CORDA2 algorithm, outputs of this formulation were compared to
108 tissue-specific metabolic models generated using CORDA and similar model parameters
(e.g. same dataset and overlapping algorithm parameters). Overall, at least 99.7% of MC reac-
tions, 88.9% of NC reactions, and 93% of unclassified reactions included in each of the previous
108 models are also included in the CORDA2 model, showing significant overlap between the




























































output of both algorithms. Furthermore, CORDA2 was approximately 2.5 times faster than
CORDA when the later was performed with five DAs for every reaction tested. Although
performing fewer DAs in CORDA led to computational times comparable to CORDA2 , the
reconstructions returned in that case are not as comprehensive. In the original CORDA pub-
lication, models reconstructed using one DA were on average 2.3% smaller than models built
using multiple DAs. The CORDA2 algorithm also showed very similar results across mul-
tiple metabolic tests when compared to the previous formulation. This analysis shows that
CORDA2 yields models similar to CORDA in composition and behavior, while being faster
and noise independent.
mfACHR Validation
To assess the performance of mfACHR when compared to gpSampler , flux distributions and
convergence speed of both formulations were compared for three different metabolic models:
a red blood cell (RBC) model,36 a platelet model,22 and the generalized human reconstruction
Recon1.34 These models have 453, 1,008, and 2,473 active reactions respectively, and were
sampled for 3·104, 7·104, 3·105 steps respectively. As an initial step in this validation, MCS
outputs of four algorithm formulations (mfACHR, mfACHR parallel, gpSampler , and gpSam-
pler parallel) were compared, and all four formulations were shown to converge to similar
steady states (supplemental information).
Next, convergence speed was assessed by computational time and number of algorithm
steps. Convergence based on number of steps was measured as the percentage of reactions
at any given point with a Kullback-Leibler divergence (KLD) of sampled flux values below
0.05 of the final distribution. KLD represents the expected logarithmic difference between two
probability distributions, and it has been previously used with a similarity threshold of 0.05
to compare sets of sampled flux distributions in metabolic models.31 The four tested formula-
Fig. 2. Conversion speed of mfACHR and gpSampler . (Top) Percentage of reactions in the model
with a KLD below 0.05 when compared to the final set of sampled points. (Bottom) Computational running
time per number of algorithm steps.




























































tions showed nearly identical conversion curves when considering the number of steps taken
(Fig. 2). When considering computational times, mfACHR performed significantly better
than gpSampler when both methods were performed without parallelization. When consider-
ing parallelization, mfACHR showed very similar computational times in the platelet model,
slightly better times in the RBC model, and significantly better times in Recon1. Differences
in computational time can be partially attributed to the fact that matrix operations performed
by mfACHR are automatically parallelized in MATLAB, while the for loops performed by
gpSampler are not. This allows for mfACHR to perform significantly faster than gpSampler
even when the latter is performed with parallelization, and explains the low relative increase in
efficiency when explicit parallelization is implemented in mfACHR. Overall, mfACHR showed
consistently faster computational times when compared to gpSampler , often in the order of
hours, while converging at the same speed in terms of number of algorithm steps.
Cancer Cell Models
Following the validation of both algorithms, a series of cell-line specific models were gen-
erated using CORDA2 and sampled using mfACHR, as described in the methods section.
Twenty-six of the cancer metabolic models were combined into four tissue categories as pre-
sented in the HPA: myeloid, lymphoid, brain, and female reproductive system (FRS) cancer
cell lines. These cancer types were chosen since they had the most number of cell lines. We
then identified metabolic reactions that have significantly different sampled flux distributions
between the four cancer categories (Fig. 3). MCS of CORDA models previously highlighted
metabolic differences between healthy and cancerous tissues.23 That is, using CORDA we cor-
related high sampled flux values with metabolic pathways known to take place in healthy or
cancerous phenotypes. Analogously, in this study we demonstrate that mfACHR sampling of
CORDA2 models generated using HPA expression data can also highlight metabolic charac-
teristics between different cancer categories. These characteristics include:
Brain tumors produce high levels of triglyceride: Lipid synthesis is an important
factor for cancer survival and progression, and it has been previously suggested as a therapeutic
target.37–40 However, while most cancer types divert fatty-acids predominantly towards the
production of phospholipids, not triglycerides,39,41 glioma cells have been shown to synthesize
triacylglycerol at high rates for membrane complex lipids.42,43 Glioma cells, as well as healthy
astrocytes and neurons, can also produce fatty acids from ketone-bodies,44,45 a metabolic
characteristic of brain cells which can further explain the high rate of fatty acid production
in glioma cells. In the MCS results presented here, brain tumors present a significantly higher
flux through glycerol-3-phosphate acyltransferase (Fig. 3) and 1-acylglycerol-3-phosphate O-
acyltransferase, enzymes responsible for triacylglycerol synthesis.
Brain and lymphoid tumors have highly active glutamine metabolism: Glu-
tamine plays an essential role in cancer metabolism,46,47 and different tumors have been shown
to utilize glutamine differently.47 Brain tumors, in particular, have been shown to accumu-
late glutamine both in vitro and in vivo.48,49 Glutamine metabolism has also been shown to
play an important role in lymphoid tissues.50 The role of this pathway in breast cancer, on the
other hand, is not well defined, since basal but not luminal breast cancer cells show glutamine-




























































Fig. 3. MCS results. Sampled flux values for six different reactions across four model categories. Boxplots
represent combined flux values for a particular reaction in all models in that cancer category. For exchange
reactions, negative values represent uptake of the particular metabolite, while positive values represent secre-
tion. Colored boxes represent values within the interquartile range (IQR), ranging from the 25th to the 75th
percentile. Horizontal line represented the median value (50th percentile), and vertical lines indicate values
within 1.5 IQR of the 25th and 75th percentiles. Outliers are represented by dots.
dependence.51 In the results presented here, brain and lymphoid cell lines show high levels of
glutamine uptake, while cell lines of the FRS show relatively low levels (Fig. 3).
Lymphoid tissues are cysteine dependent: While cysteine is not considered an es-
sential amino-acid, lymphoid tumors have been shown to contain much lower levels of cys-
tathionase, the last enzyme in the cysteine production pathway, when compared to healthy
lymphoid tissues, and are dependent on cysteine for growth.52 Targeting cysteine transporters
has also been shown to selectively target lymphoma cells,53 and cysteine uptake has been
associate with malignant progression in lymphoma cells.54 In this study, lymphoid models
presented much higher levels of cysteine uptake (Fig. 3).
Tumors show different levels of arginine dependence: Different types of cancer
respond differently to arginine deprivation.55 A study performed on 26 healthy and cancerous
cell lines found that tumor cells are much more sensitive to arginine deprivation than healthy
cells.56 Furthermore, while premyelocytic and lymphoblastic leukaemia cell lines die in about
two days of arginine deprivation, cell lines of the FRS died largely in three to four days,
and glioma cell lines died in four to five days.56 Interestingly, levels of arginine dependence
presented in the study by Scott et. al.56 correspond to sampled flux values of arginine uptake
in the present study. Myeloid cancers, the most arginine dependent, were predicted to uptake
the largest amounts of arginine, followed by models of the FRS, then brain tumors, the least
arginine dependent. Acute myeloid leukemia tumors have also been shown to be dependent
on arginine for proliferation.57
Brain tumors were also predicted to have higher fluxes through the enzyme glutamine-
fructose-6-phosphate transaminase (GF6PTA) (Fig 3), the rate limiting step in the hex-
osamines synthesis pathway (HSP), a nutrient sensor pathway.58,59 When excess nutrients
such as glucose and free fatty-acids are available, the HSP prevents cells from uptaking excess
amounts from the bloodstream.60 Furthermore, overweight and obese patients, which have




























































excess amounts of nutrients in the bloodstream, are at an overall increased risk of mortal-
ity due to cancer.61 Interestingly, sampled flux values through the HSP presented here are
anti-correlated with the increase in risk of mortality in cancer patients. According to a study
of over 57,000 cancer patients, obese patients with brain tumors have a modest increase in
mortality compared to non-obese glioma patients, while patients with cancer of the FRS have
a high increase in risk, and patients with Non-Hodgkins lymphoma, multiple myeloma, and
leukemia have a medium increase.62 Accordingly, brain tumor models in this study present
high GF6PTA flux values, while tumors of the FRS present low fluxes, and lymphoid and
myeloid tumors present intermediate values (Fig. 3). One possible explanation for this corre-
lation is that higher fluxes through the HSP can prevent cells from uptaking excess amounts of
nutrients, which in turn leads to a lower relative increase in malignancy. Further work should
help elucidate these observations in context.63,64
Sampled flux values also predict a high flux through the enzyme 4-aminobutyrate amino-
transferase in brain cancer cells. This result is expected since this enzyme is responsible for
GABA production, a pathway highly active in brain tissues. In brain cancer cells, however, this
enzyme can help produce acetyl-CoA for energy production, since larger amounts of nutrients
are diverted away from glycolysis and into the HSP. A diagram of this proposed mechanism
is presented in Fig 4A.
Primary pediatric leukemia models: We next analyzed sampled flux values in three
different types of leukemia blood sample models (AML, T-ALL, and B-ALL) to clinical pro-
Fig. 4. Model Predictions. (A) Pathways with increased activity in brain tumors. Metabolites are glucose
(GLC), fructose-6-phosphate (F6P), acetyl-CoA (ACoA), glutamine (GLN), glutamate (GLU), glucosamine-
6-phosphate (GA6P), Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), oxoglutarate (OXO), beta-
alanine (ALAB), and malonate semialdehyde (MSA). (B) Relative protein expression and sampled flux values
for proteins differentially expressed between AML and ALL pediatric patients. ODC1 participates in the reac-
tion Ornithine Decarboxylase (ORNDC), and PIK3CA participates in reactions PI4P3K, PI45P3K, PI5P3K,
and PIK3. All reactions are labeled as in the BiGG database.65




























































teomics data collected from 168 pediatric leukemia patients as described in the methods
section. Seven proteins were present both in the leukemia blood sample models and the clin-
ical dataset, of which two were significantly differentially expressed between AML and ALL
patients. The relative protein expression of these two proteins, along with the sampled flux
values of reactions associated with these proteins, are presented in Fig 4B.
Sampled flux values follow trends that correlate with protein expression in both the B-ALL
and AML models. That is, while AML patients show significantly higher expression levels of
ODC1, the AML model showed significantly higher fluxes through Ornithine Decarboxylase
(ORNDC), an ODC1 participating reaction, when compared to the B-ALL model. Likewise,
while AML patients showed significantly lower expression of PIK3CA, the AML model also
showed significantly lower sampled flux values through the PIK3CA reactions (Fig 4B).
Sampled flux values between the AML and T-ALL model did not seem to match the differential
protein expression, however. One possible explanation for this is the fact that there were
considerably fewer T-ALL patients in the clinical dataset, and fewer T-ALL samples were
used to generate the proteomics data used in the models building process (2 compared to 3
B-ALL and 4 AML). For instance, in the HPA, T-ALL ODC1 and PIK3CA protein scores are
in between B-ALL and AML values, as opposed to much closer to B-ALL values like we see in
the pediatric clinical data. This first example application to integrating RPPA leukemia data
with metabolic pathway analysis demonstrates how CORDA2 and mfACHR can also be used
to analyze clinical data and provide insight into patient-specific metabolic behaviors.
Conclusion
This work illustrates how Monte-Carlo sampling of metabolic models generated using
CORDA2 can generate valuable predictions about context specific cancer metabolism. In ap-
plying these new optimized methods to different cancer systems, we show how this work goes
beyond the identification of metabolic differences between healthy and cancerous tissues. It
identifies differences in metabolism between different cancer types, paving the way to patient-
specific metabolic models of cancer. In sum, the CORDA2 platform elucidates metabolic dif-
ferences across cancers and provides valuable knowledge of context-specific metabolic behavior
that can help guide future directed cancer therapies.
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